No Data
Top Premarket Decliners
LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $23
Oppenheimer Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Raises Target Price to $32
Express News | Astria Therapeutics: Advancing Navenibart to Phase 3 Development With Trial Initiation Expected in Q1 2025
Express News | Astria Therapeutics Inc - Navenibart Shows Favorable Safety and Well-Tolerated Profile
Astria Therapeutics Announces Positive Final Results From Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
